Feasibility and radiation induced toxicity regarding the first application of transperineal implementation of biocompatible balloon for high dose radiotherapy in patients with prostate carcinoma

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Kouloulias, Vassilis ^a,b,e   Kalogeropoulos, Theodoros ^c   Platoni, Kalliopi ^a   Georgakopoulos, John ^a   Matsopoulos, George ^b   Chaldeopoulos, Dimitris ^a   Beli, Ivelina ^a   Pantelakos, Panagiotis ^a   Asimakopoulos, Charalambos ^a   Kouvaris, John ^d   Kelekis, Nikolaos ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b NATIONAL TECHNICAL UNIVERSITY OF ATHENS   (Greece)

^c St Sawwas Anticancer Hospital   (Greece)

^d Aretaieion University   (Greece)

^e UNIVERSITY OF ATHENS   (Greece)

Author keywords

Acute toxicity; Biocompatible balloon; Prostate cancer; Radiotherapy

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BIOCOMPATIBILITY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DYSURIA; FEASIBILITY STUDY; GASTROINTESTINAL TOXICITY; HEMATURIA; HUMAN; MALE; NOCTURIA; OUTCOME ASSESSMENT; PENIS ERECTION; PERINEUM; PROSTATE CARCINOMA; QUESTIONNAIRE; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RECTUM; RECTUM DISEASE; RETROSPECTIVE STUDY; SIGMOIDOSCOPY; TENESMUS; TRANSRECTAL ULTRASONOGRAPHY; URINARY URGENCY; UROGENITAL TRACT DISEASE; VISUAL ANALOG SCALE;

ADENOCARCINOMA; AGED; FEASIBILITY STUDIES; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY, CONFORMAL; RECTUM;

EID: 84878940851     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-82     Document Type: Article

References (43)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer Statistics, 2006. CA: A Cancer Journal for Clinicians 2006, 56:106-130.
2. Ries LAG HD, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Eisner MP, Horner MJ, Howlader N, Hayat M, Hankey BF, Edwards BK. SEER Cancer Statistics Review, 1975-2003, based on November 2005 SEER data submission, posted to the SEER web site 2006, Bethesda, MD: National Cancer Institute.
3. Hummel SSE, Hemingway P, Stevenson MD, Rees A. Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. Health Technol Assess 2010, 14:1-108.
4. Zelefsky MJ, Fuks Z, Happersett L, Lee HJ, Ling CC, Burman CM, Hunt M, Wolfe T, Venkatraman ES, Jackson A, Skwarchuk M, Leibel SA. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 2000, 55:241-249. 10.1016/S0167-8140(99)00100-0, 10869739.
5. Zelefsky MJ, Fuks ZVI, Hunt M, Yamada Y, Marion C, Ling CC, Amols H, Venkatraman ES, Leibel SA. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001, 166:876-881. 10.1016/S0022-5347(05)65855-7, 11490237.
6. Alicikus ZA, Yamada Y, Zhang Z, Pei X, Hunt M, Kollmeier M, Cox B, Zelefsky MJ. Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer 2011, 117:1429-1437. 10.1002/cncr.25467, 21425143.
7. Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, Amols HI. Incidence of Late Rectal and Urinary Toxicities After Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys 2008, 70:1124-1129. 10.1016/j.ijrobp.2007.11.044, 18313526.
8. Pollack A, Hanlon A, Horwitz E, Feigenberg S, Uzzo R, Price R. Radiation therapy dose escalation for prostate cancer: a rationale for IMRT. World J Urol 2003, 21:200-208. 10.1007/s00345-003-0356-x, 12961097.
9. Wilkins A, Parker C. Treating prostate cancer with radiotherapy. Nat Rev Clin Oncol 2010, 7:583-589. 10.1038/nrclinonc.2010.135, 20714343.
10. Levy Y, Paz A, Yosef RB, Corn BW, Vaisman B, Shuhat S, Domb AJ. Biodegradable inflatable balloon for reducing radiation adverse effects in prostate cancer. J Biomed Materials Res Part B: Applied Biomaterials 2009, 91B:855-867.
11. Ben-Yosef R, Paz A, Levy Y, Alani S, Muncher Y, Shohat S, Domb A, Corn B. A Novel Device for Protecting Rectum During Prostate Cancer Irradiation: In Vivo Data on a Large Mammal Model. J Urol 2009, 181:1401-1406. 10.1016/j.juro.2008.11.010, 19157458.
12. Ohnhaus EE, Adler R. Methodological problems in the measurement of pain: A comparison between the verbal rating scale and the visual analogue scale. PAIN 1975, 1:379-384. 10.1016/0304-3959(75)90075-5, 800639.
13. Magli A, Giangreco M, Crespi M, Negri A, Ceschia T, De Giorgi G, Titone F, Parisi G, Fongione S. Erectile dysfunction after prostate three-dimensional conformal radiation therapy. Strahlenther Onkol 2012, 188:997-1002. 10.1007/s00066-012-0227-8, 23053160.
14. Bayley AJ, Catton CN, Haycocks T, Kelly V, Alasti H, Bristow R, Catton P, Crook J, Gospodarowicz MK, McLean M, Milosevic M, Warde P. A randomized trial of supine vs. prone positioning in patients undergoing escalated dose conformal radiotherapy for prostate cancer. Radiother Oncol 2004, 70:37-44. 10.1016/j.radonc.2003.08.007, 15036850.
15. Fiorino C, Reni M, Bolognesi A, Bonini A, Cattaneo GM, Calandrino R. Set-up error in supine-positioned patients immobilized with two different modalities during conformal radiotherapy of prostate cancer. Radiother Oncol 1998, 49:133-141. 10.1016/S0167-8140(98)00127-3, 10052878.
16. International Commission on Radiation Units and Measurements II Prescribing, Recording, and Reporting Photon Beam Therapy (Report 50) 1993, Bethesda, MD, http://www.icru.org/home/reports/prescribing-recording-and-reporting-photon-beam-therapy-report-50, International Commission on Radiation Units and Measurements II.
17. International Commission on Radiation Units and Measurements II Prescribing, Recording and Reporting Photon Beam Therapy (Supplement to ICRU Report 50), ICRU Report 62 1999, Bethesda, MD, http://www.icru.org/home/reports/prescribing-recording-and-reporting-photon-beam-therapy-report-62, International Commission on Radiation Units and Measurements II.
18. Kantzou IPK, Sandilos P, Gouliamos A, Kouvaris I, Sarris G, Kelekis N, Kouloulias V. Conventional versus virtual simulation for radiation treatment planning of prostate cancer: final results. J BUON 2011, 16:309-315.
19. Kitamura K, Shirato H, Seppenwoolde Y, Onimaru R, Oda M, Fujita K, Shimizu S, Shinohara N, Harabayashi T, Miyasaka K. Three-dimensional intrafractional movement of prostate measured during real-time tumor-tracking radiotherapy in supine and prone treatment positions. Int J Radiat Oncol Biol Phys 2002, 53:1117-1123. 10.1016/S0360-3016(02)02882-1, 12128110.
20. Nederveen AJ, Heide UA, Dehnad H, Moorselaar RJA, Hofman P, Lagendijk JJW. Measurements and clinical consequences of prostate motion during a radiotherapy fraction. Int J Radiat Oncol Biol Phys 2002, 53:206-214. 10.1016/S0360-3016(01)02823-1, 12007961.
21. van Herk M, Remeijer P, Rasch C, Lebesque JV. The probability of correct target dosage: dose-population histograms for deriving treatment margins in radiotherapy. Int J Radiat Oncol Biol Phys 2000, 47:1121-1135. 10.1016/S0360-3016(00)00518-6, 10863086.
22. Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, Ten Haken RK, Yorke ED. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): An Introduction to the Scientific Issues. Int J Radiat Oncol Biol Phys 2010, 76:S3-S9. 10.1016/j.ijrobp.2009.09.040, 3431964, 20171515.
23. Lawton CAF, Michalski J, El-Naqa I, Buyyounouski MK, Lee WR, Menard C, O'Meara E, Rosenthal SA, Ritter M, Seider M. RTOG GU Radiation Oncology Specialists Reach Consensus on Pelvic Lymph Node Volumes for High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 2009, 74:383-387. 10.1016/j.ijrobp.2008.08.002, 2905150, 18947938.
24. Bedford JL, Khoo VS, Oldham M, Dearnaley DP, Webb S. A comparison of coplanar four-field techniques for conformal radiotherapy of the prostate. Radiother Oncol 1999, 51:225-235. 10.1016/S0167-8140(99)00057-2, 10435818.
25. Fiorino C, Reni M, Cattaneo GM, Bolognesi A, Calandrino R. Comparing 3-, 4- and 6-fields techniques for conformal irradiation of prostate and seminal vesicles using dose-volume histograms. Radiother Oncol 1997, 44:251-257. 10.1016/S0167-8140(97)00066-2, 9380824.
26. Matsopoulos GK, Mouravliansky NA, Asvestas PA, Delibasis KK, Kouloulias V. Thoracic non-rigid registration combining self-organizing maps and radial basis functions. Med Image Anal 2005, 9:237-254. 10.1016/j.media.2004.09.002, 15854844.
27. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 1995, 31:1341-1346. 10.1016/0360-3016(95)00060-C, 7713792.
28. Kouloulias V, Kouvaris J. Cytoprotective Efficacy of Amifostine Against Radiation- Induced Rectal Toxicity: Objective and Subjective Grading Scales for Radiomucositis. Molecules 2008, 13:892-903. 10.3390/molecules13040892, 18463591.
29. Kouvaris J, Kouloulias V, Malas E, Antypas C, Kokakis J, Michopoulos S, Matsopoulos G, Vlahos L. Amifostine as Radioprotective Agent for the Rectal Mucosa during Irradiation of Pelvic Tumors. Strahlenther Onkol 2003, 179:167-174. 10.1007/s00066-003-0970-y, 12627259.
30. Crespi MDM, Schapiro M, Venables C, Zwiebel F. Working party report by the committee for minimal standards of terminology and documentation in digestive endoscopy of the european society of gastrointestinal endoscopy. Minimal standard terminology for a computerized endoscopic data base. Ad hoc task force of the committee. Am J Gastroenterol 1996, 91:191-216.
31. LENT SOMA tables table of contents. Radiother Oncol 1995, 35:17-60.
32. Livi LDB, Meattini M, Sánchez LJ, Biti GP. Organ-confined prostate cancer: treatment with high doses of radioterapy (intensity modulated radiotherapy). Actas Urol Esp 2007, 31:611-616. 10.1016/S0210-4806(07)73697-5, 17896557.
33. Ryu JK, Winter K, Michalski JM. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 gy). Int J Radiat Oncol Biol Phys 2002, 54:1036-1046. 10.1016/S0360-3016(02)03006-7, 12419429.
34. Michalski JM, Winter K, Purdy JA, Parliament M, Wong H, Perez CA, Roach M, Bosch W, Cox JD. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Int J Radiat Oncol Biol Phys 2005, 62:706-713. 10.1016/j.ijrobp.2004.11.028, 15936549.
35. Ghadjar P, Gwerder N, Manser P, Vock J, Madlung A, Mini R, Aebersold DM. High-Dose (80 Gy) Intensity-Modulated Radiation Therapy with Daily Image-Guidance as Primary treatment for Localized Prostate Cancer. Strahlenther Onkol 2010, 186:687-692. 10.1007/s00066-010-2180-8, 21136028.
36. Matzinger O, Duclos F, van den Bergh A, Carrie C, Villà S, Kitsios P, Poortmans P, Sundar S, van der Steen-Banasik EM, Gulyban A, Collette L, Bolla M. Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991. Eur J Cancer 2009, 45:2825-2834. 10.1016/j.ejca.2009.07.009, 19682889.
37. Al-Mamgani A, Heemsbergen WD, Peeters STH, Lebesque JV. Role of Intensity-Modulated Radiotherapy in Reducing Toxicity in Dose Escalation for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys 2009, 73:685-691. 10.1016/j.ijrobp.2008.04.063, 18718725.
38. Deville C, Both S, Bui V, Hwang WT, Tan KS, Schaer M, Tochner Z, Vapiwala N. Acute gastrointestinal and genitourinary toxicity of image-guided intensity modulated radiation therapy for prostate cancer using a daily water-filled endorectal balloon. Radiat Oncol 2012, 7:76. 10.1186/1748-717X-7-76, 3464898, 22621764.
39. Ray ME, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: A multi-institutional analysis. Int J Radiat Oncol Biol Phys 2006, 64:1140-1150. 10.1016/j.ijrobp.2005.07.006, 16198506.
40. Zamboglou N, Tselis N, Baltas D, Buhleier T, Martin T, Milickovic N, Papaioannou S, Ackermann H, Tunn UW. High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results. Int J Radiat Oncol Biol Phys 2013, 85:672-678. 10.1016/j.ijrobp.2012.07.004, 22929859.
41. Lettmaier S, Lotter M, Kreppner S, Strnad A, Fietkau R, Strnad V. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer. Radiother Oncol 2012, 104:181-186. 10.1016/j.radonc.2012.07.003, 22853851.
42. Kotecha R, Yamada Y, Pei X, Kollmeier MA, Cox B, Cohen GN, Zaider M, Zelefsky MJ. Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer. Brachytherapy 2013, 12:44-49. 10.1016/j.brachy.2012.05.003, 22831750.
43. Martin T, Röddiger S, Kurek R, Dannenberg T, Eckart O, Kolotas C, Heyd R, Rogge B, Baltas D, Tunn U, Zamboglou N. 3D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer. Radiother Oncol 2004, 71:35-41. 10.1016/j.radonc.2003.10.004, 15066294.